Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Robin Kate Kelley,Baek-Yeol Ryoo,Philippe Merle,Joong-Won Park,Luigi Bolondi,Stephen Lam Chan,Ho Yeong Lim,Ari David Baron,Francis Parnis,Jennifer J. Knox,Stéphane Cattan,Thomas Yau,Julie Lougheed,Steven Milwee,Anthony B. El-Khoueiry,Ann-Lii Cheng,Tim Meyer,Ghassan K. Abou-Alfa

Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

2018

Robin Kate Kelley
Baek-Yeol Ryoo
Philippe Merle
Joong-Won Park
Luigi Bolondi
Stephen Lam Chan
Ho Yeong Lim
Ari David Baron
Francis Parnis
Jennifer J. Knox
Stéphane Cattan
Thomas Yau
Julie Lougheed
Steven Milwee
Anthony B. El-Khoueiry
Ann-Lii Cheng
Tim Meyer
Ghassan K. Abou-Alfa

4088Background: C inhibits tyrosine kinases including MET, VEGFR, and AXL. In the CELESTIAL trial, C improved overall survival (OS) and progression-free survival (PFS) compared with P in pts with a...

Keywords:

Placebo
Physical therapy
Hepatocellular carcinoma
Cancer research
Systemic therapy
Sorafenib
Cabozantinib
Medicine
Tyrosine kinase
Oncology
in patient
VEGF receptors
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations